A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points (Q24651047)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points	scientific article

Statements

scholarly article

0 references

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points (English)

0 references

pharmacodynamics

1 reference

based on heuristic

inferred from title

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A O'Donnell

1

0 references

A Padhani

2

0 references

C Hayes

3

0 references

A J Kakkar

4

0 references

M Leach

5

0 references

J M Trigo

6

0 references

M Scurr

7

0 references

F Raynaud

8

0 references

S Phillips

9

0 references

W Aherne

10

0 references

A Hardcastle

11

0 references

P Workman

12

0 references

A Hannah

13

0 references

I Judson

14

0 references

language of work or name

0 references

publication date

17 October 2005

0 references

British Journal of Cancer

0 references

93

0 references

8

0 references

876-83

0 references

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

7 April 2017

A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

Functional tumor imaging with dynamic contrast‐enhanced magnetic resonance imaging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

Pitfalls in the measurement of circulating vascular endothelial growth factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

In vitro release of vascular endothelial growth factor during platelet aggregation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 September 2017

Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

30 May 2018

SU5416 delays wound healing through inhibition of TGF-beta 1 activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

30 May 2018

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

30 May 2018

Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602797

21 January 2018

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602797

21 January 2018

Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602797

21 January 2018

Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602797

21 January 2018

Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602797

21 January 2018

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602797

21 January 2018

Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 November 2018

The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 November 2018

Biotransformation of the anti-angiogenic compound SU5416.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361651

28 November 2018

Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16222321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation

1 reference

https://pubmed.ncbi.nlm.nih.gov/16222321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16222321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16222321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6602797

0 references

Dimensions Publication ID

0 references

0 references

0 references

ResearchGate publication ID

0 references

Springer Nature article ID

10.1038/sj.bjc.6602797

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24651047&oldid=1833326286"